Scientists from McMaster University and Massachusetts Institute of Technology have utilized artificial intelligence to discover and predict the mechanism of action of enterololin, a novel narrow-spectrum antibiotic targeting bacteria associated with inflammatory bowel disease (IBD) such as Crohn’s disease. This AI-driven approach represents a major breakthrough in precision antimicrobials, enabling selective targeting of harmful bacterial strains like Enterobacteriaceae while preserving beneficial microbiota. The discovery advances antibiotic research against resistant infections and epitomizes the growing role of AI in drug development, offering hope for millions affected by chronic inflammatory gastrointestinal conditions.